From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Letter to AIM Regulation: suspension of Bobbie Hilliam of Canaccord and of Celadon Pharmaceuticals shares

By Tom Winnifrith, the Sheriff of AIM | Monday 12 August 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


What has emerged today at Celadon Pharmaceuticals (CEL) is truly shocking even by the tawdry standards of the AIM sewer. The breaches of AIM Rules are explicit and clear. There is almost certainly a Companies Act breach as well and the Nomad has been grossly negligent. If heads do not roll you just have to ask what is the point of Marcus Stuttard and his team of Oxymorons at AIM regulation. I have dropped Marcus and his troops a letter, just to put them on notice.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

Time left: 04:37:16